Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical research of the effect and the safety with 0.1% bromfenac sodium hydrate ophthalmic solution and 0.1% betamethasone sodium phosphate ophthalmic, otic and nasal solution in patients with diabetic macular edema

Next Previous
X
Search
Trial Profile

Clinical research of the effect and the safety with 0.1% bromfenac sodium hydrate ophthalmic solution and 0.1% betamethasone sodium phosphate ophthalmic, otic and nasal solution in patients with diabetic macular edema

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bromfenac (Primary) ; Betamethasone sodium phosphate; Betamethasone sodium phosphate; Betamethasone sodium phosphate
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 Jan 2023 Primary endpoint (The change from baseline in retinal thickness 12 weeks after administration) has not been met, according to Results published in the Current Eye Research.
    • 01 Jan 2023 Results published in the Current Eye Research
    • 21 Feb 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top